Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Analysis of Solvency Ratios 
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

IQVIA Holdings Inc., solvency ratios (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Debt Ratios
Debt to equity 2.35 2.40 2.22 2.21 2.32 2.39 2.13 2.01 2.09 2.13 2.06 2.09 2.11 2.17 2.17 1.94 1.88 1.75 1.71 1.64 1.47 1.46 1.27
Debt to equity (including operating lease liability) 2.39 2.44 2.26 2.26 2.37 2.44 2.19 2.06 2.14 2.19 2.11 2.15 2.18 2.24 2.24 2.01 1.95 1.81 1.77 1.64 1.47 1.46 1.27
Debt to capital 0.70 0.71 0.69 0.69 0.70 0.70 0.68 0.67 0.68 0.68 0.67 0.68 0.68 0.68 0.68 0.66 0.65 0.64 0.63 0.62 0.60 0.59 0.56
Debt to capital (including operating lease liability) 0.70 0.71 0.69 0.69 0.70 0.71 0.69 0.67 0.68 0.69 0.68 0.68 0.69 0.69 0.69 0.67 0.66 0.64 0.64 0.62 0.60 0.59 0.56
Debt to assets 0.52 0.53 0.51 0.50 0.51 0.52 0.51 0.49 0.51 0.51 0.50 0.51 0.52 0.52 0.52 0.50 0.50 0.49 0.49 0.49 0.47 0.47 0.45
Debt to assets (including operating lease liability) 0.53 0.54 0.52 0.51 0.52 0.53 0.52 0.50 0.52 0.53 0.51 0.53 0.53 0.54 0.54 0.52 0.52 0.51 0.51 0.49 0.47 0.47 0.45
Financial leverage 4.47 4.53 4.34 4.39 4.53 4.56 4.22 4.09 4.12 4.16 4.11 4.09 4.08 4.15 4.16 3.87 3.73 3.54 3.49 3.36 3.12 3.07 2.83
Coverage Ratios
Interest coverage 3.21 3.50 3.79 4.25 4.84 4.79 4.51 4.02 3.45 2.98 2.30 1.91 1.65 1.54 1.77 1.77 1.81 1.80 1.84 1.83

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. IQVIA Holdings Inc. debt to equity ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.
Debt to equity (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. IQVIA Holdings Inc. debt to equity ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. IQVIA Holdings Inc. debt to capital ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.
Debt to capital (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. IQVIA Holdings Inc. debt to capital ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. IQVIA Holdings Inc. debt to assets ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.
Debt to assets (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. IQVIA Holdings Inc. debt to assets ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. IQVIA Holdings Inc. financial leverage ratio increased from Q1 2023 to Q2 2023 but then slightly decreased from Q2 2023 to Q3 2023.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. IQVIA Holdings Inc. interest coverage ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.

Debt to Equity

IQVIA Holdings Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current portion of long-term debt 1,309 1,344 1,343 152 151 152 90 91 91 147 144 149 144 142 139 100 98 100 100 100 101 101 104
Long-term debt, less current portion 12,322 12,433 11,833 12,595 12,243 12,615 12,547 12,034 12,081 12,140 12,092 12,384 12,195 11,965 11,894 11,545 11,444 11,299 11,187 10,907 10,518 10,627 10,342
Total debt 13,631 13,777 13,176 12,747 12,394 12,767 12,637 12,125 12,172 12,287 12,236 12,533 12,339 12,107 12,033 11,645 11,542 11,399 11,287 11,007 10,619 10,728 10,446
 
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,805 5,748 5,932 5,765 5,347 5,352 5,919 6,042 5,829 5,760 5,953 6,001 5,846 5,591 5,542 6,003 6,131 6,523 6,615 6,714 7,215 7,364 8,196
Solvency Ratio
Debt to equity1 2.35 2.40 2.22 2.21 2.32 2.39 2.13 2.01 2.09 2.13 2.06 2.09 2.11 2.17 2.17 1.94 1.88 1.75 1.71 1.64 1.47 1.46 1.27
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc. 5.02 4.74 4.68 3.67 4.35 4.98 4.51 4.98 5.96 6.53 6.24 6.58 5.70 5.94
Amgen Inc. 7.90 9.08 11.52 10.64 10.60 15.10 40.23 4.97 4.57 3.98 3.50 3.51 3.13 3.21 3.36 3.09 2.73 2.84 3.05
Bristol-Myers Squibb Co. 1.30 1.18 1.19 1.27 1.20 1.29 1.42 1.24 1.20 1.23 1.23 1.34 0.90 0.95 0.94 0.91 1.41 1.56 0.40
Danaher Corp. 0.42 0.38 0.39 0.39 0.41 0.43 0.47 0.49 0.54 0.48 0.50 0.53 0.57 0.62 0.84 0.72 0.54 0.32 0.30
Eli Lilly & Co. 1.80 1.70 1.69 1.52 1.58 1.97 1.77 1.88 2.20 2.56 2.35 2.94 3.51 3.99 5.60 5.88 4.50 5.68 6.44
Gilead Sciences Inc. 1.12 1.19 1.20 1.19 1.20 1.30 1.32 1.27 1.29 1.53 1.59 1.73 1.68 1.34 1.09 1.09 1.19 1.15 1.21
Johnson & Johnson 0.42 0.61 0.75 0.52 0.43 0.43 0.44 0.46 0.48 0.48 0.51 0.56 0.59 0.48 0.45 0.47 0.50 0.48 0.50
Merck & Co. Inc. 0.85 0.95 0.66 0.67 0.68 0.73 0.78 0.87 0.74 0.80 1.16 1.26 0.98 1.12 1.07 1.02 0.97 0.96 0.94
Moderna Inc. 0.04 0.05 0.04 0.05 0.05 0.04 0.04 0.04 0.02 0.05 0.04 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.03
Pfizer Inc. 0.66 0.66 0.36 0.37 0.40 0.46 0.44 0.50 0.53 0.56 0.58 0.63 0.97 0.99 0.80 0.83 0.81 0.78 0.77
Regeneron Pharmaceuticals Inc. 0.11 0.11 0.11 0.12 0.13 0.13 0.14 0.14 0.16 0.18 0.23 0.24 0.27 0.24 0.06 0.06 0.07 0.07 0.08
Thermo Fisher Scientific Inc. 0.78 0.78 0.83 0.78 0.67 0.72 0.81 0.85 0.56 0.51 0.53 0.63 0.66 0.71 0.70 0.60 0.58 0.66 0.66

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to equity = Total debt ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 13,631 ÷ 5,805 = 2.35

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to equity ratio A solvency ratio calculated as total debt divided by total shareholders’ equity. IQVIA Holdings Inc. debt to equity ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.

Debt to Equity (including Operating Lease Liability)

IQVIA Holdings Inc., debt to equity (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current portion of long-term debt 1,309 1,344 1,343 152 151 152 90 91 91 147 144 149 144 142 139 100 98 100 100 100 101 101 104
Long-term debt, less current portion 12,322 12,433 11,833 12,595 12,243 12,615 12,547 12,034 12,081 12,140 12,092 12,384 12,195 11,965 11,894 11,545 11,444 11,299 11,187 10,907 10,518 10,627 10,342
Total debt 13,631 13,777 13,176 12,747 12,394 12,767 12,637 12,125 12,172 12,287 12,236 12,533 12,339 12,107 12,033 11,645 11,542 11,399 11,287 11,007 10,619 10,728 10,446
Long-term operating lease liabilities 217 242 255 264 259 285 310 313 323 345 347 371 387 402 366 396 393 398 401
Total debt (including operating lease liability) 13,848 14,019 13,431 13,011 12,653 13,052 12,947 12,438 12,495 12,632 12,583 12,904 12,726 12,509 12,399 12,041 11,935 11,797 11,688 11,007 10,619 10,728 10,446
 
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,805 5,748 5,932 5,765 5,347 5,352 5,919 6,042 5,829 5,760 5,953 6,001 5,846 5,591 5,542 6,003 6,131 6,523 6,615 6,714 7,215 7,364 8,196
Solvency Ratio
Debt to equity (including operating lease liability)1 2.39 2.44 2.26 2.26 2.37 2.44 2.19 2.06 2.14 2.19 2.11 2.15 2.18 2.24 2.24 2.01 1.95 1.81 1.77 1.64 1.47 1.46 1.27
Benchmarks
Debt to Equity (including Operating Lease Liability), Competitors2
Moderna Inc. 0.09 0.06 0.05 0.05 0.06 0.04 0.04 0.05 0.03 0.06 0.06 0.08 0.08 0.06 0.09 0.11 0.04 0.03 0.03

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 13,848 ÷ 5,805 = 2.39

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to equity (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. IQVIA Holdings Inc. debt to equity ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.

Debt to Capital

IQVIA Holdings Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current portion of long-term debt 1,309 1,344 1,343 152 151 152 90 91 91 147 144 149 144 142 139 100 98 100 100 100 101 101 104
Long-term debt, less current portion 12,322 12,433 11,833 12,595 12,243 12,615 12,547 12,034 12,081 12,140 12,092 12,384 12,195 11,965 11,894 11,545 11,444 11,299 11,187 10,907 10,518 10,627 10,342
Total debt 13,631 13,777 13,176 12,747 12,394 12,767 12,637 12,125 12,172 12,287 12,236 12,533 12,339 12,107 12,033 11,645 11,542 11,399 11,287 11,007 10,619 10,728 10,446
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,805 5,748 5,932 5,765 5,347 5,352 5,919 6,042 5,829 5,760 5,953 6,001 5,846 5,591 5,542 6,003 6,131 6,523 6,615 6,714 7,215 7,364 8,196
Total capital 19,436 19,525 19,108 18,512 17,741 18,119 18,556 18,167 18,001 18,047 18,189 18,534 18,185 17,698 17,575 17,648 17,673 17,922 17,902 17,721 17,834 18,092 18,642
Solvency Ratio
Debt to capital1 0.70 0.71 0.69 0.69 0.70 0.70 0.68 0.67 0.68 0.68 0.67 0.68 0.68 0.68 0.68 0.66 0.65 0.64 0.63 0.62 0.60 0.59 0.56
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc. 0.83 0.83 0.82 0.79 0.81 0.83 0.82 0.83 0.86 0.87 0.86 0.87 0.85 0.86 1.12 1.14 1.27 1.30 1.27
Amgen Inc. 0.89 0.90 0.92 0.91 0.91 0.94 0.98 0.83 0.82 0.80 0.78 0.78 0.76 0.76 0.77 0.76 0.73 0.74 0.75
Bristol-Myers Squibb Co. 0.56 0.54 0.54 0.56 0.54 0.56 0.59 0.55 0.55 0.55 0.55 0.57 0.47 0.49 0.48 0.48 0.59 0.61 0.28
Danaher Corp. 0.30 0.28 0.28 0.28 0.29 0.30 0.32 0.33 0.35 0.32 0.33 0.35 0.37 0.38 0.46 0.42 0.35 0.24 0.23
Eli Lilly & Co. 0.64 0.63 0.63 0.60 0.61 0.66 0.64 0.65 0.69 0.72 0.70 0.75 0.78 0.80 0.85 0.85 0.82 0.85 0.87
Gilead Sciences Inc. 0.53 0.54 0.55 0.54 0.54 0.56 0.57 0.56 0.56 0.60 0.61 0.63 0.63 0.57 0.52 0.52 0.54 0.54 0.55
Johnson & Johnson 0.30 0.38 0.43 0.34 0.30 0.30 0.31 0.31 0.33 0.32 0.34 0.36 0.37 0.33 0.31 0.32 0.33 0.33 0.33
Merck & Co. Inc. 0.46 0.49 0.40 0.40 0.41 0.42 0.44 0.46 0.42 0.44 0.54 0.56 0.50 0.53 0.52 0.50 0.49 0.49 0.48
Moderna Inc. 0.04 0.05 0.04 0.05 0.05 0.03 0.04 0.04 0.02 0.05 0.03 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.03
Pfizer Inc. 0.40 0.40 0.26 0.27 0.28 0.32 0.31 0.33 0.35 0.36 0.37 0.39 0.49 0.50 0.45 0.45 0.45 0.44 0.43
Regeneron Pharmaceuticals Inc. 0.10 0.10 0.10 0.11 0.11 0.12 0.12 0.13 0.14 0.15 0.18 0.20 0.21 0.20 0.06 0.06 0.06 0.07 0.07
Thermo Fisher Scientific Inc. 0.44 0.44 0.45 0.44 0.40 0.42 0.45 0.46 0.36 0.34 0.35 0.39 0.40 0.42 0.41 0.37 0.37 0.40 0.40

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= 13,631 ÷ 19,436 = 0.70

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital ratio A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. IQVIA Holdings Inc. debt to capital ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.

Debt to Capital (including Operating Lease Liability)

IQVIA Holdings Inc., debt to capital (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current portion of long-term debt 1,309 1,344 1,343 152 151 152 90 91 91 147 144 149 144 142 139 100 98 100 100 100 101 101 104
Long-term debt, less current portion 12,322 12,433 11,833 12,595 12,243 12,615 12,547 12,034 12,081 12,140 12,092 12,384 12,195 11,965 11,894 11,545 11,444 11,299 11,187 10,907 10,518 10,627 10,342
Total debt 13,631 13,777 13,176 12,747 12,394 12,767 12,637 12,125 12,172 12,287 12,236 12,533 12,339 12,107 12,033 11,645 11,542 11,399 11,287 11,007 10,619 10,728 10,446
Long-term operating lease liabilities 217 242 255 264 259 285 310 313 323 345 347 371 387 402 366 396 393 398 401
Total debt (including operating lease liability) 13,848 14,019 13,431 13,011 12,653 13,052 12,947 12,438 12,495 12,632 12,583 12,904 12,726 12,509 12,399 12,041 11,935 11,797 11,688 11,007 10,619 10,728 10,446
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,805 5,748 5,932 5,765 5,347 5,352 5,919 6,042 5,829 5,760 5,953 6,001 5,846 5,591 5,542 6,003 6,131 6,523 6,615 6,714 7,215 7,364 8,196
Total capital (including operating lease liability) 19,653 19,767 19,363 18,776 18,000 18,404 18,866 18,480 18,324 18,392 18,536 18,905 18,572 18,100 17,941 18,044 18,066 18,320 18,303 17,721 17,834 18,092 18,642
Solvency Ratio
Debt to capital (including operating lease liability)1 0.70 0.71 0.69 0.69 0.70 0.71 0.69 0.67 0.68 0.69 0.68 0.68 0.69 0.69 0.69 0.67 0.66 0.64 0.64 0.62 0.60 0.59 0.56
Benchmarks
Debt to Capital (including Operating Lease Liability), Competitors2
Moderna Inc. 0.09 0.05 0.05 0.05 0.05 0.04 0.04 0.05 0.03 0.06 0.06 0.07 0.07 0.05 0.08 0.10 0.04 0.03 0.03

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 13,848 ÷ 19,653 = 0.70

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to capital (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. IQVIA Holdings Inc. debt to capital ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.

Debt to Assets

IQVIA Holdings Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current portion of long-term debt 1,309 1,344 1,343 152 151 152 90 91 91 147 144 149 144 142 139 100 98 100 100 100 101 101 104
Long-term debt, less current portion 12,322 12,433 11,833 12,595 12,243 12,615 12,547 12,034 12,081 12,140 12,092 12,384 12,195 11,965 11,894 11,545 11,444 11,299 11,187 10,907 10,518 10,627 10,342
Total debt 13,631 13,777 13,176 12,747 12,394 12,767 12,637 12,125 12,172 12,287 12,236 12,533 12,339 12,107 12,033 11,645 11,542 11,399 11,287 11,007 10,619 10,728 10,446
 
Total assets 25,977 26,036 25,739 25,337 24,223 24,413 24,969 24,689 24,033 23,937 24,467 24,564 23,837 23,183 23,078 23,251 22,892 23,068 23,109 22,549 22,498 22,626 23,235
Solvency Ratio
Debt to assets1 0.52 0.53 0.51 0.50 0.51 0.52 0.51 0.49 0.51 0.51 0.50 0.51 0.52 0.52 0.52 0.50 0.50 0.49 0.49 0.49 0.47 0.47 0.45
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc. 0.45 0.45 0.46 0.46 0.49 0.51 0.51 0.52 0.54 0.56 0.57 0.57 0.58 0.58 0.74 0.75 0.65 0.65 0.65
Amgen Inc. 0.67 0.68 0.69 0.60 0.61 0.62 0.62 0.54 0.58 0.55 0.52 0.52 0.53 0.53 0.52 0.50 0.50 0.52 0.52
Bristol-Myers Squibb Co. 0.41 0.40 0.40 0.41 0.40 0.42 0.44 0.41 0.40 0.41 0.41 0.43 0.36 0.36 0.36 0.36 0.43 0.45 0.17
Danaher Corp. 0.25 0.23 0.23 0.23 0.24 0.25 0.26 0.27 0.29 0.26 0.27 0.28 0.30 0.31 0.38 0.35 0.29 0.19 0.18
Eli Lilly & Co. 0.35 0.34 0.36 0.33 0.33 0.36 0.35 0.35 0.35 0.35 0.35 0.36 0.39 0.39 0.42 0.39 0.40 0.41 0.42
Gilead Sciences Inc. 0.40 0.40 0.41 0.40 0.40 0.42 0.42 0.39 0.41 0.44 0.45 0.46 0.48 0.43 0.40 0.40 0.42 0.41 0.42
Johnson & Johnson 0.18 0.24 0.27 0.21 0.18 0.18 0.19 0.19 0.19 0.19 0.19 0.20 0.22 0.19 0.18 0.18 0.19 0.19 0.20
Merck & Co. Inc. 0.33 0.35 0.29 0.28 0.28 0.30 0.30 0.31 0.28 0.29 0.34 0.35 0.32 0.34 0.33 0.31 0.31 0.32 0.31
Moderna Inc. 0.03 0.04 0.03 0.04 0.04 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.03 0.02
Pfizer Inc. 0.30 0.30 0.18 0.18 0.19 0.21 0.20 0.21 0.22 0.23 0.25 0.26 0.35 0.36 0.31 0.31 0.31 0.30 0.29
Regeneron Pharmaceuticals Inc. 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.13 0.15 0.16 0.17 0.15 0.05 0.05 0.05 0.05 0.06
Thermo Fisher Scientific Inc. 0.36 0.36 0.37 0.35 0.32 0.33 0.36 0.37 0.29 0.28 0.28 0.31 0.33 0.35 0.34 0.30 0.30 0.33 0.33

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= 13,631 ÷ 25,977 = 0.52

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets ratio A solvency ratio calculated as total debt divided by total assets. IQVIA Holdings Inc. debt to assets ratio deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.

Debt to Assets (including Operating Lease Liability)

IQVIA Holdings Inc., debt to assets (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Current portion of long-term debt 1,309 1,344 1,343 152 151 152 90 91 91 147 144 149 144 142 139 100 98 100 100 100 101 101 104
Long-term debt, less current portion 12,322 12,433 11,833 12,595 12,243 12,615 12,547 12,034 12,081 12,140 12,092 12,384 12,195 11,965 11,894 11,545 11,444 11,299 11,187 10,907 10,518 10,627 10,342
Total debt 13,631 13,777 13,176 12,747 12,394 12,767 12,637 12,125 12,172 12,287 12,236 12,533 12,339 12,107 12,033 11,645 11,542 11,399 11,287 11,007 10,619 10,728 10,446
Long-term operating lease liabilities 217 242 255 264 259 285 310 313 323 345 347 371 387 402 366 396 393 398 401
Total debt (including operating lease liability) 13,848 14,019 13,431 13,011 12,653 13,052 12,947 12,438 12,495 12,632 12,583 12,904 12,726 12,509 12,399 12,041 11,935 11,797 11,688 11,007 10,619 10,728 10,446
 
Total assets 25,977 26,036 25,739 25,337 24,223 24,413 24,969 24,689 24,033 23,937 24,467 24,564 23,837 23,183 23,078 23,251 22,892 23,068 23,109 22,549 22,498 22,626 23,235
Solvency Ratio
Debt to assets (including operating lease liability)1 0.53 0.54 0.52 0.51 0.52 0.53 0.52 0.50 0.52 0.53 0.51 0.53 0.53 0.54 0.54 0.52 0.52 0.51 0.51 0.49 0.47 0.47 0.45
Benchmarks
Debt to Assets (including Operating Lease Liability), Competitors2
Moderna Inc. 0.07 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.02 0.03 0.02 0.03 0.04 0.05 0.07 0.08 0.03 0.03 0.02

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 13,848 ÷ 25,977 = 0.53

2 Click competitor name to see calculations.

Solvency ratio Description The company
Debt to assets (including operating lease liability) ratio A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. IQVIA Holdings Inc. debt to assets ratio (including operating lease liability) deteriorated from Q1 2023 to Q2 2023 but then slightly improved from Q2 2023 to Q3 2023.

Financial Leverage

IQVIA Holdings Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Total assets 25,977 26,036 25,739 25,337 24,223 24,413 24,969 24,689 24,033 23,937 24,467 24,564 23,837 23,183 23,078 23,251 22,892 23,068 23,109 22,549 22,498 22,626 23,235
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,805 5,748 5,932 5,765 5,347 5,352 5,919 6,042 5,829 5,760 5,953 6,001 5,846 5,591 5,542 6,003 6,131 6,523 6,615 6,714 7,215 7,364 8,196
Solvency Ratio
Financial leverage1 4.47 4.53 4.34 4.39 4.53 4.56 4.22 4.09 4.12 4.16 4.11 4.09 4.08 4.15 4.16 3.87 3.73 3.54 3.49 3.36 3.12 3.07 2.83
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc. 11.26 10.52 10.14 8.04 8.84 9.77 8.80 9.51 10.99 11.77 10.98 11.51 9.80 10.17
Amgen Inc. 11.83 13.31 16.59 17.79 17.44 24.51 64.62 9.13 7.91 7.25 6.70 6.69 5.90 6.10 6.50 6.17 5.45 5.50 5.91
Bristol-Myers Squibb Co. 3.15 2.92 2.96 3.12 3.01 3.08 3.26 3.04 2.98 3.01 2.99 3.13 2.50 2.61 2.59 2.52 3.25 3.44 2.29
Danaher Corp. 1.67 1.64 1.65 1.68 1.72 1.76 1.80 1.84 1.90 1.82 1.87 1.92 1.92 1.97 2.22 2.05 1.89 1.66 1.64
Eli Lilly & Co. 5.16 4.95 4.75 4.65 4.71 5.51 5.03 5.44 6.21 7.42 6.79 8.27 9.10 10.25 13.35 15.07 11.20 13.91 15.32
Gilead Sciences Inc. 2.80 2.95 2.95 2.97 2.97 3.11 3.17 3.23 3.13 3.45 3.56 3.76 3.49 3.10 2.71 2.74 2.87 2.79 2.86
Johnson & Johnson 2.33 2.55 2.77 2.44 2.35 2.33 2.39 2.46 2.55 2.54 2.62 2.76 2.65 2.51 2.53 2.65 2.67 2.55 2.54
Merck & Co. Inc. 2.59 2.70 2.30 2.37 2.41 2.48 2.61 2.77 2.61 2.72 3.37 3.62 3.08 3.28 3.24 3.26 3.10 3.04 2.99
Moderna Inc. 1.45 1.29 1.28 1.35 1.45 1.45 1.62 1.74 2.07 2.41 3.31 2.86 1.69 1.18 1.26 1.35 1.27 1.26 1.25
Pfizer Inc. 2.22 2.22 1.94 2.06 2.10 2.24 2.23 2.35 2.37 2.43 2.31 2.44 2.74 2.77 2.56 2.65 2.62 2.62 2.64
Regeneron Pharmaceuticals Inc. 1.29 1.28 1.28 1.29 1.29 1.32 1.32 1.36 1.37 1.42 1.48 1.56 1.59 1.59 1.30 1.34 1.33 1.35 1.36
Thermo Fisher Scientific Inc. 2.14 2.15 2.24 2.21 2.08 2.14 2.26 2.33 1.90 1.84 1.88 2.00 2.01 2.06 2.05 1.97 1.93 2.02 2.01

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Financial leverage = Total assets ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 25,977 ÷ 5,805 = 4.47

2 Click competitor name to see calculations.

Solvency ratio Description The company
Financial leverage ratio A solvency ratio calculated as total assets divided by total shareholders’ equity. IQVIA Holdings Inc. financial leverage ratio increased from Q1 2023 to Q2 2023 but then slightly decreased from Q2 2023 to Q3 2023.

Interest Coverage

IQVIA Holdings Inc., interest coverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Selected Financial Data (US$ in millions)
Net income (loss) attributable to IQVIA Holdings Inc. 303 297 289 227 283 256 325 318 261 175 212 119 101 (23) 82 16 57 60 58 69 60 61 69
Add: Net income attributable to noncontrolling interest 5 11 7 2 9 4 12 11 9 7 7 7 4
Add: Income tax expense 51 81 71 48 70 71 71 59 12 48 44 63 (3) (5) 17 68 (1) 8 41 30 (14) 24 19
Add: Interest expense 181 169 141 128 108 94 86 90 92 94 99 102 100 108 106 109 114 114 110 106 105 107 96
Earnings before interest and tax (EBIT) 535 547 501 403 461 421 482 467 365 317 360 295 205 82 214 197 182 193 218 212 158 199 188
Solvency Ratio
Interest coverage1 3.21 3.50 3.79 4.25 4.84 4.79 4.51 4.02 3.45 2.98 2.30 1.91 1.65 1.54 1.77 1.77 1.81 1.80 1.84 1.83
Benchmarks
Interest Coverage, Competitors2
Amgen Inc. 4.54 5.43 6.51 6.22 6.83 6.97 6.40 6.60 6.46 6.48 7.64 7.44 7.62 7.62 7.85 8.09
Danaher Corp. 23.66 29.65 35.60 40.30 41.32 35.26 33.54 32.92 28.74 25.87 21.54 17.35 16.90 20.00 25.33 31.44
Gilead Sciences Inc. 8.88 9.03 8.84 7.22 5.80 6.73 6.97 9.27 10.06 7.61 2.93 2.70 2.83 0.41 5.90 6.19
Johnson & Johnson 19.09 23.89 31.49 79.71 141.63 160.27 164.15 125.46 94.27 87.06 73.87 83.07 96.82 81.36 81.56 55.49
Regeneron Pharmaceuticals Inc. 61.70 69.61 73.97 82.80 108.62 116.35 163.24 163.75 139.74 104.12 68.20 67.97 72.22 108.12 90.22 81.43
Thermo Fisher Scientific Inc. 5.98 6.64 8.28 11.56 13.59 15.70 16.73 17.49 19.94 19.52 17.58 14.07 10.78 7.93 7.66 7.02

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

1 Q3 2023 Calculation
Interest coverage = (EBITQ3 2023 + EBITQ2 2023 + EBITQ1 2023 + EBITQ4 2022) ÷ (Interest expenseQ3 2023 + Interest expenseQ2 2023 + Interest expenseQ1 2023 + Interest expenseQ4 2022)
= (535 + 547 + 501 + 403) ÷ (181 + 169 + 141 + 128) = 3.21

2 Click competitor name to see calculations.

Solvency ratio Description The company
Interest coverage ratio A solvency ratio calculated as EBIT divided by interest payments. IQVIA Holdings Inc. interest coverage ratio deteriorated from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.